SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Inlyta

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 2012.
Why 3/10
Inlyta is an already-approved, marketed drug with no pending PDUFA date, Advisory Committee, or pivotal readout in the next ~12 months. The next catalysts are patent litigation outcomes and eventual generic entry, but these are not hard dated binary events. Inlyta contributes roughly $923M in annual revenue to Pfizer's $63B+ total, making it a small part of a diversified giant, so even a major change would have limited impact on the stock.
Actionable Insight NEUTRAL

Inlyta is a mature, declining-revenue product with no upcoming binary catalysts. Watch for resolution of patent litigation against Sandoz and Alkem, which will determine the timing of generic entry (currently expected 2027-2028). Any settlement or court ruling on the axitinib patents could accelerate or delay generic competition, but even a major patent loss would have a modest impact on Pfizer's overall revenue given Inlyta's ~$923M annual contribution versus Pfizer's $63B+ total revenue.

Price Chart

Loading chart...

Executive Summary

Inlyta (axitinib) is Pfizer's oral VEGFR-targeted kinase inhibitor approved since 2012 for advanced renal cell carcinoma (RCC), both as a single agent after prior therapy and in first-line combinations with avelumab or pembrolizumab. It generated roughly $923 million in 2025 revenue, down 6% year-over-year, reflecting competitive pressure and approaching loss of exclusivity. Sandoz has received tentative FDA approval for a generic version, and Pfizer is engaged in patent litigation against both Sandoz and Alkem to delay generic entry, currently expected in 2027-2028. Inlyta is a small part of Pfizer's diversified $63B+ revenue base, so its individual performance has limited impact on the stock.

How It Works

Inlyta (axitinib) is an oral targeted cancer drug that blocks a family of proteins called vascular endothelial growth factor receptors (VEGFR-1, -2, and -3). These receptors are involved in the growth of new blood vessels that tumors need to get oxygen and nutrients. By inhibiting these receptors, Inlyta starves the tumor by cutting off its blood supply. It is more selective for VEGFR than older similar drugs, which may reduce some side effects.

Trial Status

Inlyta is FDA-approved and commercially marketed. It was initially approved in 2012 for advanced RCC after one prior systemic therapy, and later expanded to first-line use in combination with avelumab (2019) and pembrolizumab. Pfizer continues to study axitinib in combination regimens through investigator-sponsored and company-sponsored trials, including a Phase 3 continued-access study (NCT05059522) estimated to complete in December 2026.

The Two-Sided Case

▲ Bull Case4
Inlyta remains a meaningful contributor to Pfizer's oncology portfolio with ~$923M in 2025 revenue, and it benefits from label expansions into first-line RCC in combination with avelumab (Bavencio) and pembrolizumab (Keytruda).
Pfizer is actively defending its patents through litigation, which could delay generic entry beyond current expectations and extend the product's revenue stream.
The axitinib market is projected to grow at ~8.5% CAGR through 2033, suggesting continued demand even as generics enter.
Inlyta is part of Pfizer's broader oncology franchise that generated $25.4B in 2025, and the company continues to invest in combination studies that could support further use.
▼ Bear Case4
Revenue declined 6% in 2025 to ~$923M, and the downward trend is likely to continue as generic competition approaches.
Sandoz has received tentative FDA approval for a generic version of axitinib, and Pfizer's patent lawsuit against Sandoz (filed Nov 2024) creates uncertainty about how long exclusivity will last.
Pfizer dropped its patent suit against Alkem in July 2026, though it left the door open to refile, signaling potential weakness in the patent wall.
Generic entry is expected in 2027-2028, which would significantly erode Inlyta's branded sales.

Upcoming Catalysts

  • Resolution of patent litigation against Sandoz (filed Nov 2024, Delaware) could determine generic entry timing.
  • Resolution of patent litigation against Alkem (filed May 2026, Delaware) after Pfizer dropped an earlier suit in July 2026.
  • Potential generic axitinib launch, currently expected in 2027-2028, which would significantly reduce branded Inlyta sales.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 16

Hover a chip for the title
1 s206.q4cdn.com2 pfizer.com3 pharmacompass.com4 nasdaq.com5 drugs.com6 hellopharmacist.com7 msn.com8 news.bloomberglaw.com9 news.bloomberglaw.com10 patsnap.com11 drugpatentwatch.com12 pfizer.com13 accessdata.fda.gov14 inlyta.pfizerpro.com15 en.wikipedia.org16 cognitivemarketresearch.com